Pre-clinical development of farnesyltransferase inhibitors

Cancer and Metastasis Reviews

Volumn 17, Issue 2, 1998, Pages 203-210

  Lobell, Robert B ^a   Kohl, Nancy E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cancer; Prenylation; Ras

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE METHYL ESTER; PROTEIN FARNESYLTRANSFERASE; RAS PROTEIN;

COLON CARCINOMA; GENE MUTATION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE RAS; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW;

ALKYL AND ARYL TRANSFERASES; ANIMALS; CELL DIVISION; DRUG DESIGN; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HUMANS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; RAS PROTEINS;

EID: 0031849288     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006018922878     Document Type: Review

References (54)

1. Barbacid M: ras Genes. Ann Rev Biochem 56: 779-827, 1987
2. Boguski MS, McCormick F: Proteins regulating Ras and its relatives. Nature 366: 643-654, 1993
3. Wittinghofer A, Nassar N: How Ras-related proteins talk to their effectors. Trends Bioch Sci 21: 488-491, 1996
4. Willumsen BM, Norris K, Papageorge AG, Hubbert NL, Lowy DR: Harvey murine sarcoma virus p21 ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus. EMBO J 3: 2581-2585, 1984
5. Casey PJ, Solski PA, Der CJ, Buss JE: p21ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci USA 86: 8323-8327, 1989
6. Hancock JF, Magee AI, Childs JE, Marshall CJ: All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 57: 1167-1177, 1989
7. Schafer WR, Kim R, Sterne R, Thorner J, Kim S-H, Rine J: Genetic and pharmacological suppression of oncogenic mutations in RAS genes of yeast and humans. Science 245: 379-385, 1989
8. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature (London) 343: 425-430, 1990
9. Zhang FL, Casey PJ: Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 65: 241-269, 1996
10. Andres AD, Seabra MC, Brown MS, Armstrong SA, Smeland TE, Cremers FPM, Goldstein JL: cDNA cloning of component A of Rab geranylgeranyltransferase and demonstration of its role as a Rab escort protein. Cell 73: 1091-1099, 1993
11. Boyartchuk VL, Ashby MN, Rine J: Modulation of Ras and a-factor function by carboxyl-terminal proteolysis. Science 275: 1796-1800, 1997
12. Chen Y, Ma Y-T, Rando RR: Solubilization, partial purification, and affinity labeling of the membrane-bound isoprenylated protein endoprotease. Biochemistry 35: 3227-3237, 1996
13. Hrycyna CA, Clarke S: Farnesyl cysteine C-terminal methyl-transferase activity is dependent upon the STE14 gene product in Saccharomyces cerevisiae. Mol Cell Biol 10: 5071-5076, 1990
14. Marr RS, Blair LC, Thorner J: Saccharomyces cerevisiae STE14 gene is required for COOH-terminal methylation of a-factor mating pheromone. J Biol Chem 265: 20057-20060, 1990
15. ras to the plasma membrane. Cell 63: 133-139, 1990
16. Hancock JF, Cadwallader K, Marshall CJ: Methylation and proteolysis are essential for efficient membrane binding of prenylated p21K-ras(B). EMBO J 10: 641-646, 1991
17. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ: Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 89: 6403-6407, 1992
18. Goldstein JL, Brown MS, Stradley SJ, Reiss Y, Gierasch LM: Nonfarnesylated tetrapeptide inhibitors of protein farnesyltransferase. J Biol Chem 266: 15575-15578, 1991
19. Pompliano DL, Rands E, Schaber MD, Mosser SD, Anthony NJ, Gibbs JB: Steady-state kinetic mechanism of Ras farnesyl:protein transferase. Biochemistry 31: 3800-3807, 1992
20. Kohl NE, Wilson FR, Mosser SD, Giuliani E, DeSolms SJ, Conner MW, Anthony NJ, Holtz WJ, Gomez RP, Lee T-J, Smith RL, Graham SL, Hartman GD, Gibbs JB, Oliff A: Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci USA 91: 9141-9145, 1994
21. Omer CA, Kohl NE: CAAX-competitive inhibitors of farnesyltransferase as anti-cancer agents. Trends in Pharmacological Sciences 18: 437-445, 1997
22. Nagasu T, Yoshimatsu K, Rowell C, Lewis MD, Garcia AM: Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res 55: 5310-5314, 1995
23. Lerner EC, Qian Y, Blaskovich MA, Fossum RD, Vogt A, Sun J, Cox AD, Der CJ, Hamilton AD, Sebti SM. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem 270: 26802-26806, 1995
24. James GL, Goldstein JL, Brown MS, Rawson TE, Somers TC, McDowell RS, Crowley CW, Lucas BK, Levinson AD, James C, Marsters J: Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science 260: 1937-1942, 1993
25. Williams TM, Ciccarone TM, MacTough SC, Bock RL, Conner MW, Davide JP, Hamilton K, Koblan KS, Kohl NE, Kral AM, Mosser SD, Omer CA, Pompliano DL, Rands E, Schaber MD, Shah D, Wilson FR, Gibbs JB, Graham SL, Hartman GD, Oliff AI, Smith RL: 2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase. J Med Chem 39: 1345-1348, 1996
26. Bishop WR, Bond R, Petrin J, Wang L, Patton R, Doll R, Njoroge C, Catino J, Schwartz J, Windsor W, Syto R, Schwartz J, Carr D, James L, Kirschmeier P: Novel tricyclic inhibitors of farnesyl protein transferase. J Biol Chem 270: 30611-30618, 1995
27. Mallams AK, Njoroge FG, Doll RJ, Snow ME, Kaminski JJ, Rossman RR, Vibulbhan B, Bishop WR, Kirschmeier P, Liu M, Bryant MS, Alvarez C, Carr D, James L, King I, Li Z, Lin C-C, Nardo C, Petrin J, Remiszewski SW, Taveras AG, Wang S, Wong J, Catino J, Girijavallabhan V, Ganguly AK: Antitumor 8-chlorobenzyocycloheptapyridines: a new class of selective, nonpeptidic, nonsulfhydryl inhibitors of ras farnesylation. Bioorg Med Chem 5: 93-99, 1997
28. Hara M, Akasaka K, Akinaga S, Okabe M, Nakano H, Gomez R, Wood D, Uh M, Tamanoi F: Identification of Ras farnesyltransferase inhibitors by microbial screening. Proc Natl Acad Sci USA 90: 2281-2285, 1993
29. Manne V, Yan N, Carboni JM, Tuomari AV, Ricca CS, Brown JG, Andahazy ML, Schmidt RJ, Patel D, Zahler R, Weinmann R, Der CJ, Cox AD, Hunt JT, Gordon EM, Barbacid M, Seizinger BR: Bisubstrate inhibitors of farnesyltransferase: A novel class of specific inhibitors of ras transformed cells. Oncogene 10: 1763-1779, 1995
30. Prendergast GC, Davide JP, deSolms SJ, Giuliani EA, Graham SL, Gibbs JB, Oliff A, Kohl NE: Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol 14: 4193-4202, 1994
31. Kohl NE, Omer CA, Conner MW, Anthony NJ, Davide JP, deSolms SJ, Giuliani EA, Gomez RP, Graham SL, Hamilton K, Handt LK, Hartman GD, Koblan KS, Kral AM, Miller PJ, Mosser SD, O'Neill TJ, Rands E, Schaber MD, Gibbs JB, Oliff A: Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nature Med 1: 792-797, 1995
32. Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A, Rosen N: A peptidomimetic inhibitor of farnesyl: protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 55: 5302-5309, 1995
33. Sun J, Qian Y, Hamilton AD, Sebti SM: Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res 55: 4243-4247, 1995
34. Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, Bishop WR, Pai J-K: K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272: 14459-14464, 1997
35. Rowell CA, Kowalczyk JJ, Lewis MD, Garcia AM: Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J Biol Chem 272: 14093-14097, 1997
36. James GL, Goldstein JL, Brown MS: Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem 270: 6221-6226, 1995
37. Zhang FL, Kirschmeier P, Carr D, James L, Bond RW, Wang L, Patton R, Windsor WT, Syto R, Zhang R, Bishop WR: Characterization of Ha-Ras, N-Ras, Ki-Ras4a, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I. J Biol Chem 272: 10232-10239, 1997
38. Hancock JF, Cadwallader K, Paterson H, Marshall CJ: A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of Ras proteins. EMBO J 10: 4033-4039, 1991
39. rho proteins. J Biol Chem 267: 20033-20038, 1992
40. Lebowitz PF, Casey PJ, Prendergast GC, Thissen JA: Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhobB. J Biol Chem 272: 15591-15594, 1997
41. Clark GJ, Kinch MS, Rogers-Graham K, Sebti SM, Hamilton AD, Der CJ: The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation. J Biol Chem 272: 10608-10615, 1997
42. Diamond RH, Cressman DE, Laz TM, Abrams CS, Taub R: PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth. Mol Cell Biol 14: 3752-3762, 1994
43. Cates CA, Michael RL, Stayrook KR, Harvey KA, Burke YD, Randall SK, Crowell PL, Crowell DN: Prenylation of oncogenic human PTP-CAAX protein tyrosine phosphatases. Cancer Lett 110: 49-55, 1996
44. Yaglom JA, Goldberg AL, Finley D, Sherman MY: The molecular chaperone Ydj1 is required for the p34CDC28-dependent phosphorylation of the cyclin Cln3 that signals its degradation. Mol Cell Biol 16: 3679-3684, 1996
45. Kanazawa M, Terada K, Kato S, Mori M: HSDJ, a human homolog of DnaJ, is farnesylated and is involved in protein import into mitochondria. J Biochem 121: 890-895, 1997
46. Gotte K, Girzalsky W, Linkert M, Baumgart E, Kammerer S, Kunau W-H, Erdmann R: Pex19p, a farnesylated protein essential for peroxisome biogenesis. Mol Cell Biol 18: 616-628, 1998
47. James GL, Brown MS, Cobb MH, Goldstein JL: Benzodiazepine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in H-Ras-transformed Rat-1 cells, but not in untransformed cells. J Biol Chem 269: 27705-27714, 1994
48. Lebowitz PF, Sakamuro D, Prendergast GC: Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Res 57: 708-713, 1997
49. Barrington RE, Subler MA, Rands E, Omer CA, Miller PJ, Hundley JE, Koester SK, Troyer DA, Bearss DJ, Conner MW, Gibbs JB, Hamilton K, Koblan KS, Mosser SD, O'Neill TJ, Schaber MD, Senderak ET, Windle JJ, Oliff A, Kohl NE: A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol Cell Biol 18: 85-92, 1998
50. Prendergast GC, Davide JP, Lebowitz PF, Wechsler-Reya R, Kohl NE: Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors. Cancer Res 56: 2626-2632, 1996
51. Bernhard EJ, Kao G, Cox AD, Sebti SM, Hamilton AD, Muschel RJ, McKenna WG: The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res 56: 1727-1730, 1996
52. Bernhard EJ, McKenny WG, Hamilton AD, Sebti SM, Qian Y, Wu JM, Muschel RJ: Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res 58: 1754-1761, 1998
53. Moasser MM, Sepp-Lorenzino L, Kohl NE, Oliff A, Balog A, Su D-S, Danishefsky SJ, Rosen N: Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci USA 95: 1369-1374, 1998
54. Fokstuen T, Bendix-Rabo Y, Zhou J-N, Karlson J, Platz A, Shoshan MC, Hansson J, Linder S: The ras farnesylation inhibitor BZA-5B increases the resistance to cisplatin in a human melanoma cell line. Anticancer Res 17: 2347-2352, 1997